|
News Releases
|
|
|
February 27, 2013 |
AVEO AND ASTELLAS ANNOUNCE FDA ADVISORY COMMITTEE TO REVIEW TIVOZANIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA |
February 26, 2013 |
MEDIVATION AND ASTELLAS PROVIDE ADDITIONAL SUPPORT TO METASTATIC PROSTATE CANCER PATIENTS THROUGH DONATIONS TO INDEPENDENT NON-PROFIT PATIENT ASSISTANCE ORGANIZATION |
February 19, 2013 |
HUMANA AND ASTELLAS FORM RESEARCH COLLABORATION TO IMPROVE HEALTH CARE DELIVERY FOR SENIORS |
February 19, 2013 |
ASTELLAS TO DRIVE PGA TOUR’S NEW WOMEN’S INITIATIVE |
February 13, 2013 |
ASTELLAS HIGHLIGHTS PROGRESS TO ADVANCE CARE OF PATIENTS WITH GENITOURINARY CANCERS AT ASCO-GU ANNUAL MEETING |
February 13, 2013 |
ENZALUTAMIDE DATA PRESENTED AT ASCO GU SYMPOSIUM |
February 12, 2013 |
AVEO AND ASTELLAS REPORT FINAL OVERALL SURVIVAL RESULTS FROM TIVO-1 |
January 30, 2013 |
ENZALUTAMIDE DATA TO BE PRESENTED AT ASCO GU SYMPOSIUM |
January 30, 2013 |
AVEO AND ASTELLAS ANNOUNCE PRESENTATIONS OF TIVOZANIB CLINICAL DATA AT 2013 ASCO GENITOURINARY CANCERS SYMPOSIUM |
January 22, 2013 |
ASTELLAS’ NEW HEADQUARTERS FOR THE AMERICAS AWARDED LEED GOLD CERTIFICATION |
January 16, 2013 |
FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR TARCEVA® (ERLOTINIB) TABLETS FOR GENETICALLY DISTINCT FORM OF ADVANCED LUNG CANCER |
January 10, 2013 |
AGENSYS CELEBRATES OPENING OF NEW FACILITY IN SANTA MONICA |
December 04, 2012 |
ASTELLAS ANNOUNCES ACCEPTANCE OF U.S. NEW DRUG APPLICATION FOR TACROLIMUS EXTENDED RELEASE CAPSULES |
December 03, 2012 |
AVEO AND ASTELLAS ANNOUNCE INITIATION OF PATIENT ENROLLMENT IN PHASE 2 TRIAL OF TIVOZANIB IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER |
November 28, 2012 |
AVEO AND ASTELLAS ANNOUNCE FDA ACCEPTANCE OF NDA FILING FOR TIVOZANIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA |
November 20, 2012 |
ASTELLAS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR TARCEVA® AS A FIRST-LINE THERAPY IN GENETICALLY DISTINCT FORM OF NON-SMALL CELL LUNG CANCER |
November 01, 2012 |
ASTELLAS APPOINTS NEW VICE PRESIDENT OF SCIENTIFIC AND MEDICAL AFFAIRS |
October 22, 2012 |
MYRBETRIQ™ (MIRABEGRON), OVERACTIVE BLADDER TREATMENT FROM ASTELLAS, NOW AVAILABLE THROUGH U.S. PHARMACIES |
October 11, 2012 |
ASTELLAS ANNOUNCES COMPLIANCE OFFICER FOR THE AMERICAS |
October 02, 2012 |
ASTELLAS PHARMA US RECEIVES CEO CANCER GOLD STANDARD ACCREDITATION |
October 01, 2012 |
AVEO AND ASTELLAS ANNOUNCE NEW DATA PRESENTED AT ESMO 2012 CONGRESS DEMONSTRATING THE SAFETY AND TOLERABILITY PROFILE OF TIVOZANIB IN PATIENTS WITH ADVANCED KIDNEY CANCER |
September 30, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE NEW DATA FROM XTANDI® (ENZALUTAMIDE) PIVOTAL STUDY |
September 28, 2012 |
AVEO AND ASTELLAS ANNOUNCE SUBMISSION OF NEW DRUG APPLICATION FOR TIVOZANIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA |
September 24, 2012 |
ASTELLAS SUBMITS U.S. NEW DRUG APPLICATION FOR TACROLIMUS EXTENDED RELEASE CAPSULES, A PROPHYLAXIS OF ORGAN REJECTION IN TRANSPLANT RECIPIENTS |
September 14, 2012 |
PERSONAL CONNECTIONS DRIVE EMPLOYEE PARTICIPATION FOR CHANGING TOMORROW DAY AT ASTELLAS |
September 13, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE XTANDI® (ENZALUTAMIDE) IS NOW AVAILABLE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
|
August 31, 2012 |
PATIENT INFORMATION XTANDI® (EX TAN DEE)(ENZALUTAMIDE) CAPSULES |
August 31, 2012 |
FULL PRESCRIBING INFORMATION FOR XTANDI® (ENZALUTAMIDE) CAPSULES |
August 31, 2012 |
U.S. FDA APPROVES XTANDI® (ENZALUTAMIDE) AFTER PRIORITY REVIEW FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXE |
August 15, 2012 |
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES RESULTS FROM PHASE 3 AFFIRM TRIAL OF ENZALUTAMIDE |
August 06, 2012 |
ASTELLAS TO CLOSE UROGENIX, NORTH CAROLINA-BASED UROLOGY RESEARCH FACILITY |
August 03, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE PDUFA ACTION DATE FOR ENZALUTAMIDE NDA |
July 25, 2012 |
ASTELLAS AND FUJITA HEALTH UNIVERSITY DISCOVER NEURONAL MATURATION DEFICITS IN PATIENTS SUFFERING FROM SCHIZOPHRENIA AND BIPOLAR DISORDER |
July 24, 2012 |
ENZALUTAMIDE GRANTED PRIORITY REVIEW BY U.S. FDA FOR THE POTENTIAL TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY |
July 23, 2012 |
ADDITION OF TARCEVA® (ERLOTINIB) TO NEXAVAR® (SORAFENIB) DID NOT PROVIDE
ADDITIONAL BENEFIT TO PATIENTS WITH UNRESECTABLE LIVER CANCER VERSUS NEXAVAR ALONE IN PHASE 3 TRIAL |
Jun 28, 2012 |
FDA APPROVES OVERACTIVE BLADDER TREATMENT MYRBETRIQ™ (MIRABEGRON) FROM ASTELLAS |
Jun 28, 2012 |
FULL PRESCRIBING INFORMATION FOR MYRBETRIQ (MIRABEGRON) EXTENDED RELEASE TABLETS |
Jun 13, 2012 |
ASTELLAS SENDS 1,300 VOLUNTEERS TO ‘GIVE KIDS THE WORLD,’LARGEST SINGLE GROUP OF VOLUNTEERS IN VILLAGE HISTORY |
Jun 12, 2012 |
ASTELLAS AND DNDI TO COLLABORATE ON NEW DRUG DISCOVERY RESEARCH FOR THE TREATMENT OF NEGLECTED TROPICAL DISEASES |
Jun 06, 2012 |
MEDIVATION AND ASTELLAS PROVIDE UPDATE ON PREVAIL ENROLLMENT |
Jun 04, 2012 |
ASTELLAS AND AMBIT INITIATE PHASE 2B DOSE FINDING STUDY OF QUIZARTINIB AS MONOTHERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA |
Jun 04, 2012 |
GOVERNOR QUINN ANNOUNCES 150 NEW JOBS AT ASTELLAS HEADQUARTERS FOR THE AMERICAS IN ILLINOIS |
Jun 04, 2012 |
AGENSYS AND SEATTLE GENETICS ANNOUNCE INTERIM PHASE I DATA FROM ASG-5ME CLINICAL TRIAL FOR PROSTATE CANCER |
Jun 04, 2012 |
AVEO AND ASTELLAS ANNOUNCE TAURUS PATIENT PREFERENCE CLINICAL STUDY COMPARING TIVOZANIB WITH SUNITINIB IN FIRST-LINE KIDNEY CANCER |
Jun 02, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE ENZALUTAMIDE DATA RELATING TO QUALITY OF LIFE MEASURES AND EXTENSION OF TIME TO FIRST SKELETAL-RELATED EVENT |
May 30, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE INITIATION OF EXPANDED ACCESS PROGRAM FOR ENZALUTAMIDE (FORMERLY MDV3100) IN THE UNITED STATES |
May 21, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE SUBMISSION OF NEW DRUG APPLICATION FOR ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY |
May 21, 2012 |
ASTELLAS STATEMENT REGARDING NEW OVERACTIVE BLADDER GUIDELINES |
May 18, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE ENZALUTAMIDE (FORMERLY MDV3100) DATA TO BEPRESENTED AT ASCO ANNUAL MEETING 2012 |
May 16, 2012 |
AVEO AND ASTELLAS ANNOUNCE POSITIVE FINDINGS FROM TIVO-1 SUPERIORITY STUDY OF TIVOZANIB IN FIRST LINE ADVANCED RCC |
April 05, 2012 |
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF MIRABEGRON - INVESTIGATIONAL OVERACTIVE BLADDER TREATMENT FROM ASTELLAS |
March 13, 2012 |
ASTELLAS ONCOLOGY CYCLING TEAM DEBUTS WITH 12 RIDERS FOR 2012 |
February 21, 2012 |
ASTELLAS HIRES SENIOR VICE PRESIDENT OF NEW
GLOBAL MEDICAL AFFAIRS ORGANIZATION |
January 31, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE POSITIVE RESULTS FROM THE PHASE 3 AFFIRM TRIAL OF MDV3100 IN PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR CHEMOTHERAPY |
January 06, 2012 |
ASTELLAS AND THERAVANCE ANNOUNCE TERMINATION OF LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR VIBATIV® (TELAVANCIN) FOR INJECTION |
January 03, 2012 |
AVEO AND ASTELLAS ANNOUNCE TIVOZANIB SUCCESSFULLY DEMONSTRATED PROGRESSION-FREE
SURVIVAL SUPERIORITY OVER SORAFENIB IN PATIENTS WITH ADVANCED RENAL CELL CANCER IN PHASE
3 TIVO-1 TRIAL |
December 21, 2011 |
ZOGENIX AND ASTELLAS AGREE TO END CO-PROMOTION FOR
SUMAVEL DOSEPRO EFFECTIVE MARCH 31, 2012 |
December 01, 2011 |
ASTELLAS ADDS TWO KEY SENIOR EXECUTIVES AT AGENSYS, INC. |
November 11, 2011 |
ASTELLAS SIGNS UNITED NATIONS GLOBAL COMPACT |
November 03, 2011 |
MEDIVATION AND ASTELLAS ANNOUNCE POSITIVE SURVIVAL DATA FROM INTERIM ANALYSIS OF PHASE 3 AFFIRM TRIAL OF MDV3100 IN MEN WITH ADVANCED PROSTATE CANCER |
September 28, 2011 |
SEVEN CHICAGO AREA SERVICE PROJECTS TOP OFF CHANGING TOMORROW DAY AT ASTELLAS |
August 28, 2011 |
ASTELLAS PHARMA INC.: ANNOUNCEMENT OF REGULATORY SUBMISSION FOR MIRABEGRON (YM178), A TREATMENT FOR OVERACTIVE BLADDER, IN U.S. AND EUROPE |
August 15, 2011 |
ASTELLAS EXPANDS LEADERSHIP TEAM WITH SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND GOVERNMENT AFFAIRS |
July 26, 2011 |
MERCK TO ACQUIRE RIGHTS TO VERNAKALANT I.V. IN CANADA, MEXICO AND THE UNITED STATES FROM ASTELLAS |
June 06, 2011 |
ASTELLAS ANNOUNCES NEW STUDY RESULTS SHOWING INCREASED SURVIVAL RATE FOR METASTATIC PANCREATIC CANCER |
June 03, 2011 |
TARCEVA NEARLY DOUBLED THE TIME PEOPLE WITH A GENETICALLY DISTINCT TYPE OF LUNG CANCER LIVED WITHOUT THEIR DISEASE GETTING WORSE |
May 19, 2011 |
ASTELLAS ANNOUNCES VICE PRESIDENT OF SALES AND MARKETING FOR U.S. ONCOLOGY FRANCHISE |
May 17, 2011 |
ASTELLAS ANNOUNCES POSITIVE PHASE III RESULTS SHOWING MIRABEGRON IMPROVES KEY OAB SYMPTOMS |
May 03, 2011 |
ASTELLAS STRENGTHENS GLOBAL DEVELOPMENT TEAM |
January 28, 2011 |
EARLY SUCCESSFUL READOUT OF TARCEVA STUDY IN A DISTINCT FORM OF LUNG CANCER |
January 10, 2011 |
ASTELLAS TO REVIEW STRATEGIC BUSINESS ALTERNATIVES FOR PROSIDION SUBSIDIARY |
November 16, 2010 |
2010 NSTA NEW SCIENCE TEACHER ACADEMY FELLOWS ANNOUNCED
|
November 02, 2010 |
ASTELLAS DONATES 150 LAPTOP COMPUTERS TO HELP INNER-CITY CHICAGO STUDENTS
ASTELLAS ANNOUNCES RETIREMENT OF DONALD RICE AND APPOINTMENT OF SEF KURSTJENS AS CEO AND PRESIDENT OF AGENSYS, INC.
|
October 28, 2010 |
NEW SURVEY SHOWS REAL-WORLD ACTIVITIES CAN HELP REINVIGORATE STUDENT INTEREST IN SCIENCE EDUCATION
|
September 27, 2010 |
LEXISCAN® (REGADENOSON) INJECTION STUDY IN SUBJECTS WITH ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PRESENTED AS LATE-BREAKER AT AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY 2010
NEW SMARTPHONE APP LAUNCHES FOR CARDIAC IMAGING TEST
|
September 17, 2010 |
ASTELLAS MOBILIZES 1,300+ EMPLOYEES IN THE AMERICAS TO PARTICIPATE IN FIRST ANNUAL \'CHANGING TOMORROW DAY' |
September 15, 2010 |
ASTELLAS AWARDS SCHOLARSHIPS TO 12 TRANSPLANT RECIPIENTS AND DONORS WHO EMBODY HOPE, COURAGE AND ACHIEVEMENT |
September 15, 2010 |
ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE RECIPIENTS TO THE 2011 ROSE PARADE® |
September 1, 2010 |
AGENSYS, AN AFFILIATE OF ASTELLAS, ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF AGS-16M8F FOR RENAL CANCER |
June 28, 2010 |
ASTELLAS ANNOUNCES ORAL PRESENTATION OF SGLT2 INHIBITOR DETAILING
"SAFETY AND EFFICACY IN PATIENTS WITH TYPE 2 DIABETES AT THE
"AMERICAN DIABETES ASSOCIATION MEETING |
June 9, 2010 |
ASTELLAS COMPLETES ACQUISITION OF OSI PHARMACEUTICALS
|
June 8, 2010 |
ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF TENDER OFFER FOR SHARES OF OSI
|
June 3, 2010 |
ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF INITIAL TENDER OFFER FOR SHARES OF OSI AND ANNOUNCES SUBSEQUENT OFFER PERIOD |
May 17, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO JUNE 2, 2010 |
May 16, 2010 |
ASTELLAS PHARMA INC. TO ACQUIRE OSI PHARMACEUTICALS, INC.
|
May 03, 2010 |
NEW SCIENCE EDUCATION PROGRAM RESPONDS TO PRESIDENT\'S
"CALL TO HELP YOUNG PEOPLE EXCEL IN SCIENCE
|
April 29, 2010 |
GOVERNOR QUINN ANNOUNCES ASTELLAS PHARMA U.S.
"CHOOSES ILLINOIS FOR NEW HEADQUARTERS
|
April 29, 2010 |
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA® RECEIVED APPROVAL IN THE EUROPEAN UNION
"FOR MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
April 26, 2010 |
OSI PHARMACEUTICALS ANNOUNCES THAT "RADIANT", AN INTERNATIONAL PHASE III TARCEVA
"ADJUVANT TRIAL IN NON-SMALL CELL LUNG CANCER, COMPLETES ENROLLMENT
|
April 23, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO MAY 17, 2010
|
April 16, 2010 |
FDA APPROVES TARCEVA AS A MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
|
April 05, 2010 |
NUMBER OF AMERICANS WILLING TO DONATE ORGANS RISES,
"BUT STILL NOT KEEPING PACE WITH NEED
|
March 31, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO APRIL 23, 2010
|
March 29, 2010 |
ASTELLAS SIGNS CONFIDENTIALITY AGREEMENT WITH OSI
|
March 19, 2010 |
ASTELLAS ANNOUNCES CHANGES TO DIRECTOR NOMINEES FOR ELECTION TO OSI
"PHARMACEUTICALS\' BOARD OF DIRECTORS
|
March 19, 2010 |
ASTELLAS ANNOUNCES EXPIRATION OF HSR WAITING PERIOD FOR OSI TENDER OFFER
|
March 19, 2010 |
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA® RECEIVED A POSITIVE OPINION FROM HEALTH AUTHORITIES IN THE EUROPEAN UNION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
March 16, 2010 |
ASTELLAS ANNOUNCES FULL SLATE OF INDEPENDENT DIRECTOR NOMINEES FOR ELECTION AT OSI
"PHARMACEUTICALS\' 2010 ANNUAL STOCKHOLDERS MEETING
|
March 15, 2010 |
ASTELLAS RESPONDS TO OSI PHARMACEUTICALS\' REJECTION
|
March 02, 2010 |
ASTELLAS PHARMA INC. COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF OSI PHARMACEUTICALS FOR $52 PER SHARE IN CASH
|
March 01, 2010 |
ASTELLAS PHARMA INC. OFFERS TO ACQUIRE OSI PHARMACEUTICALS FOR $52.00 PER SHARE IN CASH
|
January 15, 2010 |
FDA EXTENDS REVIEW PERIOD FOR TARCEVA APPLICATION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
January 13, 2010 |
SUMAVELTM DOSEPROTM AVAILABLE IN THE UNITED STATES TO TREAT ACUTE MIGRAINE AND CLUSTER HEADACHES
|
January 12, 2010 |
OSI PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND 2009 FULL YEAR TARCEVA SALES AT JP MORGAN HEALTHCARE CONFERENCE
|
December 29, 2009 |
U.S. PATENT AND TRADEMARK OFFICE GRANTS REISSUED PATENT REPLACING OSI PHARMACEUTICALS\' TARCEVA® COMPOSITION OF MATTER PATENT
|
December 16, 2009 |
FDA ADVISORY COMMITTEE RECOMMENDS AGAINST APPROVING TARCEVA FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
December 07, 2009 |
ASTELLAS INDUCTED INTO NATIONAL MINORITY TRANSPLANT HALL OF FAME MOTTEP HONORS ASTELLAS FOR COMMITMENT TO TRANSPLANT COMMUNITY
|
November 16, 2009 |
OSI PHARMACEUTICALS ANNOUNCES TARCEVA TO BE REVIEWED BY THE FDA\'S ONCOLOGIC DRUGS
"ADVISORY COMMITTEE FOR USE AS A FIRST-LINE MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER |
November 05, 2009 |
THERAVANCE AND ASTELLAS ANNOUNCE THE COMMERCIAL LAUNCH OF
VIBATIVTM (telavancin) IN THE UNITED STATES
|
October 28, 2009 |
CARDIOME AND ASTELLAS ANNOUNCE INITIATION OF PATIENT ENROLMENT IN ACT 5 TRIAL |
October 26, 2009 |
DONATE LIFE ILLINOIS, ASTELLAS AND THE CHICAGO BEARS PARTNER TO
"TACKLE THE SHORTAGE IN HONOR OF BEARS LEGEND, WALTER PAYTON
|
October 22, 2009 |
ZOGENIX AND ASTELLAS ANNOUNCE DATA PUBLISHED SHOWING THE
BENEFITS OF SUMAVELTM DOSEPROTM NEEDLE-FREE DELIVERY SYSTEM |
October 02, 2009 |
NEW ANALYSIS SUPPORTS TOLERABILITY OF LEXISCAN® (regadenoson) INJECTION FOR PHARMACOLOGIC MYOCARDIAL PERFUSION IMAGING STUDIES
|
|
September 22, 2009
|
ASTELLAS AWARDS EDUCATIONAL SCHOLARSHIPS TO SIX TRANSPLANT RECIPIENTS WHO EMBODY THE SPIRIT OF GIVING BACK
|
|
September 21, 2009
|
ASTELLAS AND THE NATIONAL SCIENCE TEACHERS ASSOCIATION
ANNOUNCE 2009 CLASS OF LOCAL SCIENCE EDUCATORS
|
|
September 17, 2009
|
U.S. PATENT AND TRADEMARK OFFICE ISSUES A NOTICE OF ALLOWANCE IN OSI PHARMACEUTICALS'
REISSUE APPLICATION ON TARCEVA(R) COMPOSITION OF MATTER PATENT
|
|
September 15, 2009
|
ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE
RECIPIENTS TO THE 2010 ROSE PARADE®
|
|
September 11, 2009
|
THERAVANCE AND ASTELLAS ANNOUNCE FDA APPROVAL OF VIBATIV™
(telavancin) FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
|
|
August 17, 2009
|
CHICAGO MAYOR HONORS ASTELLAS' EXCELLENCE IN LEARNING, DEVELOPMENT
|
|
August 13, 2009
|
UPDATE ON ASTELLAS' REQUEST FOR RIGOROUS TESTING AND SAFETY-RELATED
LABELING FOR ANTI-REJECTION MEDICATIONS
|
|
August 10, 2009
|
ASTELLAS SEEKS RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS
UNIQUE NEEDS OF TRANSPLANT PATIENTSREQUIRE SPECIAL CARE TO PRESERVE THEIR GIFT OF
LIFE
ADDITIONAL CLINICAL
TRIAL TO BE CONDUCTED FOR KYNAPID UNDER FDA SPECIAL PROTOCOL AGREEMENT
|
|
August 1, 2009
|
NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA EXTENDED SURVIVAL IN PATIENTS
WITH ADVANCED NON-SMALL CELL LUNG CANCER WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY
|
|
July 13, 2009
|
NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA IMPROVED OVERALL SURVIVAL WHEN
USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SMALL
CELL LUNG CANCER
|
|
July 6, 2009
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF A TARCEVA(R) SUPPLEMENTAL NEW DRUG APPLICATION
IN PANCREATIC CANCER FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION; TARCEVA'S
SNDA IS GRANTED PRIORITY REVIEW DESIGNATION BY THE FDA
|
|
August 3, 2009
|
ZOGENIX
AND ASTELLAS ENTER EXCLUSIVE CO-PROMOTION AGREEMENT IN THE US FOR NEWLY APPROVED
SUMAVELTM DOSEPROTM
|
|
July 7, 2009
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF A TARCEVA(R) SUPPLEMENTAL NEW DRUG APPLICATION
IN PANCREATIC CANCER FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION; TARCEVA'S
SNDA IS GRANTED PRIORITY REVIEW DESIGNATION BY THE FDA
|
|
June 25, 2009
|
ASTELLAS INFORMS CUSTOMERS OF MARKET WITHDRAWAL OF SPECIFIC
PRODUCT LOTS
|
|
June 15, 2009
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF TARCEVA SUPPLEMENTAL NEW DRUG APPLICATION
FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION
|
|
June 04, 2009
|
ASTELLAS ADDS CNS THERAPY
AREA LEADER TO GLOBAL R&D TEAM
|
|
June 01, 2009
|
ASTELLAS HIRES
NEW VICE PRESIDENT OF COMPLIANCE
|
|
May 30, 2009
|
DATA FROM THE PHASE III ATLAS STUDY SHOW TARCEVA IN COMBINATION WITH AVASTIN AS
FIRST-LINE MAINTENANCE THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG
CANCER
|
|
May 28, 2009
|
ASTELLAS RECEIVES
FDA APPROVAL FOR USE OF PROGRAF® (TACROLIMUS) IN CONJUNCTION WITH
MYCOPHENOLATE MOFETIL (MMF) IN KIDNEY TRANSPLANT RECIPIENTS
|
|
May 28, 2009
|
ASTELLAS ANNOUNCES
NEW VICE PRESIDENT OF MARKETING
|
|
May 28, 2009
|
PHASE 3 TRIAL INITIATED TO EVALUATE COMBINATION THERAPY OF NEXAVAR(R) AND TARCEVA(R)
IN PATIENTS WITH LIVER CANCER
|
|
May 14, 2009
|
DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL
WHEN USED AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
|
|
April 1, 2009
|
ASTELLAS
APPOINTS NEW US PRESIDENT AND CEO
|
|
March 31, 2009
|
ASTELLAS LAUNCHES VAPRISOL® (CONIVAPTAN HYDROCHLORIDE INJECTION)
PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA
|
|
March 19, 2009
|
OSI PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR TARCEVA
AS A FIRST-LINE MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER
|
|
March 16, 2009
|
ASTELLAS TO TERMINATE OFFER FOR CV THERAPEUTICS
|
|
March 6, 2009
|
ASTELLAS TO NOMINATE TWO DIRECTORS AND SUBMIT PROPOSAL TO REMOVE
REMAINING FOUR DIRECTORS OF CV THERAPEUTICS
|
|
February 27, 2009
|
ASTELLAS FILES
LAWSUIT AGAINST CV THERAPEUTICS
|
|
February 27, 2009
|
ASTELLAS COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF CV THERAPEUTICS
FOR $16 PER SHARE IN CASH
|
|
February 23, 2009
|
ASTELLAS PHARMA ISSUES STATEMENT REGARDING CV THERAPEUTICS REJECTION
OF ALL-CASH PROPOSAL
|
|
February 10, 2009
|
OSI PHARMACEUTICALS ANNOUNCES NOTIFICATION OF ANDA FILING FOR TARCEVA
|
|
February 2, 2009
|
PHASE III STUDY SHOWED TARCEVA IN COMBINATION WITH AVASTIN AS FIRST-LINE MAINTENANCE
THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG CANCER
|
|
January 27, 2009
|
ASTELLAS
PROPOSES TO ACQUIRE CV THERAPEUTICS FOR $16 PER SHARE IN CASH
|
|
November 26, 2008
|
TARCEVA® (ERLOTINIB) ENDORSED BY THE U.K.'S NATIONAL INSTITUTE FOR
HEALTH AND CLINICAL EXCELLENCE FOR USE IN PATIENTS WITH ADVANCED NON-SMALL CELL
LUNG CANCER
|
|
November 7, 2008
|
PHASE III STUDY (SATURN) SHOWED TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL AS A
FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
|
|
October 22, 2008
|
FDA APPROVES ASTELLAS'
VAPRISOL® CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE
TREATMENT OF HYPONATREMIA
|
|
October 14, 2008
|
ASTELLAS
RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2009
ROSE PARADE®
|
|
October 06, 2008
|
GENENTECH AND OSI PHARMACEUTICALS ANNOUNCE TOPLINE RESULTS FROM PHASE III STUDY
EVALUATING THE COMBINATION OF AVASTIN AND TARCEVA AS SECOND-LINE TREATMENT FOR ADVANCED
NON-SMALL CELL LUNG CANCER
|
|
October 01, 2008
|
ASTELLAS JOINS FORCES WITH THE NATIONAL SCIENCE TEACHERS ASSOCATION TO SUPPORT LOCAL
SCIENCE EDUCATORS
|
|
August 11, 2008
|
CARDIOME
AND ASTELLAS ANNOUNCE RECEIPT OF FDA APPROVABLE LETTER FOR KYNAPIDTM
|
|
June 24, 2008
|
ASTELLAS LAUNCHES LEXISCANTM (REGADENOSON) INJECTION FOR USE AS A PHARMACOLOGIC
STRESS AGENT IN RADIONUCLIDE MYOCARDIAL PERFUSION IMAGING (MPI)
|
|
April 10, 2008
|
CV THERAPEUTICS
AND ASTELLAS ANNOUNCE FDA APPROVAL FOR LEXISCANTM (REGADENOSON) INJECTION
|
|
March 25, 2008
|
CIRCULATION
PUBLISHES DATA SHOWING KYNAPID (VERNAKALANT HYDROCHLORIDE) INJECTION RAPIDLY CONVERTED
SHORT-DURATION ATRIAL FIBRILLATION TO SINUS RHYTHM
|
|
Feburary 27, 2008
|
OSI PHARMACEUTICALS SEEKS TO STRENGTHEN TARCEVA PATENT BY FILING RE-ISSUE APPLICATION
WITH THE U.S. PATENT AND TRADEMARK OFFICE
|
|
January 22, 2008
|
FDA APPROVES ADDITIONAL INDICATION FOR ASTELLAS MYCAMINE®
|
|
January 21, 2008
|
CARDIOME AND ASTELLAS ANNOUNCE REGULATORY UPDATE
|
|
December 14, 2007
|
OSI PHARMACEUTICALS ANNOUNCES LAUNCH DATE OF TARCEVA(R) (ERLOTINIB) IN JAPAN
|
|
December 11, 2007
|
FDA
ADVISORY COMMITTEE RECOMMENDS APPROVAL OF KYNAPID FOR ACUTE ATRIAL FIBRILLATION
|
|
November 7, 2007
|
STUDY SHOWS VERNAKALANT
HYDROCHLORIDE IS EFFECTIVE IN CONVERSION TO NORMAL HEART RHYTHM IN ATRIAL FIBRILLATION
PATIENTS FOLLOWING CARDIAC SURGERY
|
|
October 25, 2007
|
STUDY SHOWS
VAPRISOL® IS EFFECTIVE IN INCREASING SERUM SODIUM LEVELS AND WELL-TOLERATED
IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA
|
|
October 22, 2007
|
TARCEVA(R) (ERLOTINIB) EARNS APPROVAL FOR LUNG CANCER PATIENTS IN JAPAN
|
|
October 22, 2007
|
ADENOSCAN® PATENT LAWSUITS SETTLED
|
|
October 22, 2007
|
THERAVANCE
RECEIVES FDA APPROVABLE LETTER FOR TELAVANCIN FOR THE TREATMENT OF COMPLICATED SKIN
AND SKIN STRUCTURE INFECTIONS
|
|
October 17, 2007
|
ASTELLAS
PHARMA US, INC. AND THE INTERNATIONAL TRANSPLANT NURSES SOCIETY (ITNS) COLLABORATE
ON CONTENT FOR TRANSPLANT EXPERIENCE PROGRAM
|
|
October 15, 2007
|
OSI PHARMACEUTICALS PROVIDES ADDITIONAL INFORMATION ABOUT US SALES OF TARCEVA
|
|
October 11, 2007
|
ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS
TO RIDE FLOAT IN 2008 ROSE PARADE
|
|
September 18, 2007
|
OSI PHARMACEUTICALS ANNOUNCES PATENT TERM EXTENSION FOR TARCEVA(R) (ERLOTINIB)
|
|
September 7, 2007
|
OSI PHARMACEUTICALS SUMMARIZES DATA PRESENTED ON TARCEVA(R) (ERLOTINIB) AT THE 12TH
WORLD CONGRESS ON LUNG CANCER MEETING
|
|
June 5, 2007
|
OSI PHARMACEUTICALS SUMMARIZES DATA ON TARCEVA(R) (ERLOTINIB) AT THE 2007 AMERICAN
SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
|
|
April 25, 2007
|
OSI PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE III TARCEVA(R) STUDY PUBLISHED IN THE
JOURNAL OF CLINICAL ONCOLOGY SHOWED SURVIVAL IMPROVEMENT IN PATIENTS WITH PANCREATIC
CANCER
|
|
March 02, 2007
|
FDA APPROVES ASTELLAS VAPRISOL®
FOR THE TREATMENT OF HYPERVOLEMIC HYPONATREMIA
|
|
February 26, 2007
|
Astellas Pharma US, Inc.'s "TRANSPLANT EXPERIENCE" PROGRAM RECEIVES
NATIONAL RECOGNITION
|
|
February 19, 2007
|
CARDIOME
AND ASTELLAS ANNOUNCE ACCEPTANCE OF NDA FOR REVIEW
|
|
January 29, 2007
|
OSI PHARMACEUTICALS ANNOUNCES EUROPEAN REGULATORY APPROVAL OF TARCEVA(R) FOR TREATMENT
OF PATIENTS WITH PANCREATIC CANCER
|
|
November 15, 2006
|
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA(R) RECEIVED POSITIVE OPINION FROM HEALTH
AUTHORITIES IN EUROPEAN UNION FOR THE TREATMENT OF PATIENTS WITH PANCREATIC CANCER
|
|
September 21, 2006
|
OSI PHARMACEUTICALS LAUNCHES STUDY OF TARCEVA(R) AS ADJUVANT TREATMENT FOR NON-SMALL
CELL LUNG CANCER
|
|
October 29, 2006
|
ASTELLAS
PHARMA US, INC., GLAXOSMITHKLINE, AND VESIcare® (SOLIFENACIN SUCCINATE) SPONSOR
THE #18 RACE CAR AT ATLANTA MOTOR SPEEDWAY TO RAISE AWARENESS ABOUT OVERACTIVE BLADDER
|
|
July 27, 2006
|
OSI PHARMACEUTICALS ANNOUNCES THAT ROCHE HAS RECEIVED NEGATIVE CHMP OPINION IN EUROPEAN
UNION ON TARCEVA(R) IN PANCREATIC CANCER
|
|
July 25, 2006
|
STUDY
DEMONSTRATES IMPROVED RENAL FUNCTION AND LIPID VALUES IN KIDNEY TRANSPLANT PATIENTS
ON PROGRAF ® COMPARED TO PATIENTS TAKING NEORAL ®
|
|
June 6, 2006
|
OSI SUMMARIZES CLINICAL DATA ON TARCEVA(R) AT THE 2006 AMERICAN SOCIETY OF CLINICAL
ONCOLOGY (ASCO) MEETING
|
|
June 5, 2006
|
RESULTS FROM A RANDOMIZED PHASE II TRIAL SUGGESTED THE COMBINATIONS OF AVASTIN(R)
PLUS TARCEVA(R) AND AVASTIN PLUS CHEMOTHERAPY IMPROVED PROGRESSION- FREE SURVIVAL
IN ADVANCED NON-SMALL CELL LUNG CANCER
|
|
April 26, 2006
|
ASTELLAS LAUNCHES VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA IN HOSPITALIZED
PATIENTS
|
|
April 17, 2006
|
OSI PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TARCEVA(R)
IN JAPAN
|
|
April 3, 2006
|
ASTELLAS
TO ACQUIRE AMEVIVE® (ALEFACEPT)
|
|
April 1, 2006
|
ASTELLAS
RECEIVES FDA APPROVAL OF PROGRAF® (TACROLIMUS) FOR USE IN HEART TRANSPLANT RECIPIENTS
|
|
March 31, 2006
|
NEW DRUG
APPLICATION SUBMITTED FOR RSD1235
|
|
Feburary 1, 2006
|
OSI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER NET SALES FOR TARCEVA(R)'S INTERNATIONAL
LAUNCH; TARCEVA WORLD-WIDE SALES REACHED $309 MILLION IN 2005
|
|
January 19, 2006
|
ASTELLAS
EDUCATES AND INFORMS PHYSICIANS AND PATIENTS ON CHANGES TO PROTOPIC LABEL IN U.S.
|
|
January 11, 2006
|
OSI PHARMACEUTICALS ANNOUNCES NET U.S. TARCEVA(R) SALES FOR FOURTH QUARTER AND YEAR-END
2005; NARROWS MACUGEN(R) GUIDANCE & UPDATES CASH POSITION ON BALANCE SHEET
|
|
December 30, 2005
|
FDA APPROVES
ASTELLAS' VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA
|
|
November 7, 2005
|
THERAVANCE AND ASTELLAS
TO COLLABORATE ON TELAVANCIN, INVESTIGATIONAL ANTIBIOTIC FOR SERIOUS INFECTIONS
|
|
November 3, 2005
|
MULTIMEDIA NEWS RELEASE -- FDA APPROVES TARCEVA(R) IN COMBINATION WITH GEMCITABINE
CHEMOTHERAPY FOR TREATMENT OF LOCALLY ADVANCED, INOPERABLE OR METASTATIC PANCREATIC
CANCER
|
|
November 2, 2005
|
FDA APPROVES TARCEVA(R) IN COMBINATION WITH GEMCITABINE CHEMOTHERAPY FOR TREATMENT
OF LOCALLY ADVANCED, INOPERABLE OR METASTATIC PANCREATIC CANCER; TARCEVA NOW APPROVED
FOR ADVANCED NON-SMALL CELL LUNG CANCER AND PANCREATIC CANCER
|
|
October 19, 2005
|
CARDIOME AND ASTELLAS INITIATE ACT 4 STUDY
|
|
October 12, 2005
|
OSI REITERATES CONFIDENCE IN TARCEVA
|
|
September 21, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA(R) GRANTED APPROVAL IN THE EUROPEAN UNION
FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
|
|
September 13, 2005
|
FDA ADVISORY PANEL RECOMMENDS TARCEVA(R) APPROVAL FOR PANCREATIC CANCER; COMMITTEE
SUPPORTS NEW INDICATION FOR EGFR INHIBITOR TARCEVA
|
|
August 10, 2005
|
RAGADENOSON MEETS PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL
|
|
August 8, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA(R) TO BE REVIEWED BY THE FDA'S ONCOLOGIC DRUGS
ADVISORY COMMITTEE FOR USE IN PANCREATIC CANCER
|
|
July 13, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED APPROVAL IN CANADA FOR THE TREATMENT
OF ADVANCED NON-SMALL CELL LUNG CANCER
|
|
June 27, 2005
|
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA-R- RECEIVES POSITIVE OPINION IN EU FOR
THE TREATMENT OF PATIENTS WITH ADVANCED LUNG CANCER
|
|
June 2, 2005
|
OSI PHARMACEUTICALS ANNOUNCES ISSUANCE OF ADDITIONAL U.S. PATENT FOR TARCEVA; EXTENDS
PATENT EXCLUSIVITY
|
|
May 24, 2005
|
THREE CLINICAL STUDIES
DEMONSTRATE ONCE-DAILY MODIFIED RELEASE PROGRAF® FORMULA TO BE PROMISING TREATMENT
OPTION
|
|
May 24, 2005
|
NEW STUDIES
OF IMMUNOSUPPRESSIVE REGIMENS LIMITING OR AVOIDING THE USE OF STEROIDS SHOW EXCELLENT
GRAFT SURVIVAL IN TRANSPLANT RECIPIENTS ON A PROGRAF®-BASED (TACROLIMUS) REGIMEN
|
|
May 17, 2005
|
DATA FROM TARCEVA CLINICAL TRIAL PROGRAM PRESENTED AT AMERICAN SOCIETY OF CLINICAL
ONCOLOGY ANNUAL MEETING
|
|
May 16, 2005
|
DATA FROM TARCEVA-TM- CLINICAL TRIAL PROGRAM PRESENTED AT AMERICAN SOCIETY OF CLINICAL
ONCOLOGY ANNUAL MEETING; EGFR AMPLIFICATION / MUTATION ANALYSIS FROM THE REGISTRATION
BR.21 TRIAL PRESENTED
|
|
May 14, 2005
|
PHASE III STUDY OF TARCEVA IN COMBINATION WITH CHEMOTHERAPY IMPROVES SURVIVAL IN
PANCREATIC CANCER PATIENTS
|
|
May 13, 2005
|
ANTI-FUNGAL
AGENT MYCAMINETM AVAILABLE TO PHYSICIANS
|
|
May 2, 2005
|
OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE FILING OF A SUPPLEMENTAL NEW DRUG APPLICATION
TO THE FDA FOR TARCEVA -TM- IN PANCREATIC CANCER
|
|
April 1, 2005
|
YAMANOUCHI,
FUJISAWA UNITE TO FORM ASTELLAS PHARMA US, INC., NORTH AMERICAN HEADQUARTERS TO
BE IN CHICAGO
|
|
March 22, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED FIRST EUROPEAN APPROVAL IN SWITZERLAND;
FIRST AND ONLY AGENT APPROVED IN ITS CLASS TO SHOW A SURVIVAL BENEFIT
|
|
January 27, 2005
|
DATA FROM PHASE III STUDY SHOW TARCEVA PLUS GEMCITABINE SIGNIFICANTLY IMPROVES SURVIVAL
COMPARED TO GEMCITABINE ALONE IN ADVANCED PANCREATIC CANCER PATIENTS
|
|
November 22, 2004
|
OSI PHARMACEUTICALS ANNOUNCES LAUNCH OF TARCEVA-TM
|
|
November 18, 2004
|
FDA APPROVES TARCEVA-TM- FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER;
ONLY TARGETED EGFR THERAPY SHOWN TO IMPROVE SURVIVAL IN ADVANCED NON-SMALL CELL
LUNG CANCER
|
|
September 30, 2004
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF TARCEVA NEW DRUG APPLICATION FOR REVIEW
BY THE U.S. FOOD AND DRUG ADMINISTRATION
|
|
September 20, 2004
|
TARCEVA PLUS GEMCITABINE IMPROVES SURVIVAL COMPARED TO GEMCITABINE ALONE IN FIRST-LINE
PANCREATIC CANCER PATIENTS
|
|
September 10, 2004
|
GENENTECH AND OSI PHARMACEUTICALS INITIATE PHASE IIIB CLINICAL TRIAL OF TARCEVA
IN ADVANCED NON-SMALL CELL LUNG CANCER
|
|
August 26, 2004
|
OSI PHARMACEUTICALS ANNOUNCES ROCHE FILING OF TARCEVA -TM- MARKETING APPLICATION
WITH EUROPEAN HEALTH AUTHORITIES
|
|
August 2, 2004
|
OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE COMPLETION OF NEW DRUG APPLICATION FOR
FDA APPROVAL OF TARCEVA
|
|
June 29, 2004
|
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA HAS BEEN ACCEPTED INTO THE FDA'S PILOT
1 PROGRAM
|
|
July 16, 2004
|
OSI PHARMACEUTICALS AND GENENTECH ENTER INTO CO-PROMOTION AND MANUFACTURING AGREEMENTS
FOR TARCEVA
|
|
June 5, 2004
|
EARLY CLINICAL DATA EVALUATING THE COMBINATION OF AVASTIN AND TARCEVA YIELD INITIAL
PROMISING RESULTS IN SEVERAL CANCERS
|
|
April 26, 2004
|
TARCEVA EXTENDS SURVIVAL OF PATIENTS WITH RELAPSED NON-SMALL CELL LUNG CANCER
|
|
March 19, 2004
|
OSI PHARMACEUTICALS INITIATES PHASE II STUDY OF TARCEVA IN NON-SMALL CELL LUNG CANCER
PATIENTS WITH POOR PERFORMANCE STATUS
|
|
January 21, 2004
|
OSI PHARMACEUTICALS INITIATES 'ROLLING' SUBMISSION OF A NEW DRUG APPLICATION WITH
THE FDA FOR TARCEVA-TM- IN NON-SMALL CELL LUNG CANCER
|
|
November 11, 2003
|
OSI PHARMACEUTICALS INITIATES PHASE II 'DOSE-TO-RASH' DOSE ESCALATION STUDY FOR
TARCEVA--ERLOTINIB HCL--
|
|
October 1, 2003
|
PHASE III TRIALS OF TARCEVA PLUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG
CANCER DO NOT MEET PRIMARY EFFICACY ENDPOINT
|
|
August 8, 2003
|
TARCEVA -- ERLOTINIB HCL -- PHASE II CLINICAL TRIAL INITIATED IN PATIENTS WITH MALIGNANT
GLIOMA
|
|
June 3, 2003
|
OSI SUMMARIZES KEY CLINICAL DATA FOR TARCEVA - ERLOTINIB HCL - PRESENTED AT ASCO
|
|
May 31, 2003
|
TARCEVA -- ERLOTINIB HCL -- SHOWS ENCOURAGING SAFETY PROFILE AND ACTIVITY IN PHASE
I CLINICAL STUDY IN PATIENTS WITH MALIGNANT GLIOMA
|
|
April 10, 2003
|
OSI PHARMACEUTICALS UPDATES INVESTORS ON STATUS OF TARCEVA DEVELOPMENT PROGRAM
|
|
January 30, 2003
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA INTERNATIONAL PHASE III REFRACTORY / ADVANCED
NON-SMALL CELL LUNG CANCER CLINICAL TRIAL HAS REACHED ITS TARGET ENROLLMENT GOAL
|
|
January 28, 2003
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA; INTERNATIONAL PHASE III PANCREATIC CANCER
CLINICAL TRIAL HAS REACHED ITS TARGET ENROLLMENT GOAL
|
|
September 23, 2002
|
OSI PHARMACEUTICALS RECEIVES SECOND FDA FAST-TRACK DESIGNATION FOR TARCEVA; ANNOUNCES
AMENDMENTS TO TARCEVA DEVELOPMENT PLAN
|
|
September 12, 2002
|
INTERNATIONAL TRIAL EVALUATING TARCEVA IN LUNG CANCER COMPLETES PATIENT ENROLLMENT
|
|
August 19, 2002
|
OSI PHARMACEUTICALS AND GENENTECH PROVIDE UPDATE ON STATUS OF TARCEVA ROGRAM
|
|
August 1, 2002
|
TARCEVA U.S. PHASE III NON-SMALL CELL LUNG CANCER CLINICAL TRIAL COMPLETES PATIENT
ENROLLMENT
|
|
May 14, 2002
|
GENENTECH AND OSI PHARMACEUTICALS ANNOUNCE FDA FAST-TRACK DESIGNATION FOR TARCEVA
|
|
May 2, 2002
|
OSI PHARMACEUTICALS ANNOUNCES COMPLETION OF INITIAL COHORT IN PHASE III PANCREATIC
CANCER TRIAL FOR TARCEVA
|